Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Clinical trial NCT04085315 · COMPLETED

Trial details

NCT number: NCT04085315
Sponsor: Collin Blakely
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lung Cancer Metastatic EGFR Gene Mutation

Start date: 2019-11-12
Primary completion: 2025-10-20
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.